Cellosaurus Capan-1 (CVCL_0237)

Cell line name Capan-1
Synonyms CaPan-1; CAPAN-1; Capan 1; CAPAN 1; Capan1; CAPAN1
Accession CVCL_0237
Resource Identification Initiative To cite this cell line use: Capan-1 (RRID:CVCL_0237)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: KuDOS 95 cell line panel.
Part of: MD Anderson Cell Lines Project.
From: Memorial Sloan-Kettering Cancer Center; New York; USA.
Registration: Memorial Sloan-Kettering Cancer Center Office of Technology Development; SK 923.
Doubling time: ~50-100 hours (DSMZ).
Microsatellite instability: Stable (MSS) (Sanger).
Sequence variation: KRAS p.Gly12Val (PubMed=8026879).
Sequence variation: TP53 p.Ala159Val (PubMed=8026879).
Omics: Deep exome analysis.
Omics: Deep proteome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: Proteome analysis by 2D-DE/MS.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Misspelling: CANPAN-1; In Cosmic 2434105.
Disease Pancreatic ductal adenocarcinoma (NCIt: C9120)
Derived from metastatic site: Liver.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children: CVCL_S022 (Capan-1 SimpleCell O-GalNAc); CVCL_0A59 (Capan1M9)
Sex of cell Male
Category Cancer cell line
STR profile Source(s): AddexBio; ATCC; CLS; Cosmic-CLP; DSMZ; KCLB; PubMed=25877200

Markers:
AmelogeninX
CSF1PO11
D13S3179
D16S53913,14
D18S5112
D21S1128,30
D3S135815
D5S81811
D7S82010,11
D8S117914,16
FGA24
Penta D9,13
Penta E10,12
TH016
TPOX8,11
vWA16
Web pages http://www.pawefish.path.cam.ac.uk/PancCellLineDescriptions/capan-1.html
https://www.mskcc.org/research-advantage/support/technology/tangible-material/capan-1-human-pancreatic-adenocarcinoma-cell-line
http://tcpaportal.org/mclp/
Publications

PubMed=327080; DOI=10.1093/jnci/59.1.221
Fogh J., Fogh J.M., Orfeo T.
One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.
J. Natl. Cancer Inst. 59:221-226(1977)

PubMed=833871; DOI=10.1093/jnci/58.2.209
Fogh J., Wright W.C., Loveless J.D.
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
J. Natl. Cancer Inst. 58:209-214(1977)

PubMed=6935474; DOI=10.1093/jnci/66.2.239
Wright W.C., Daniels W.P., Fogh J.
Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis.
J. Natl. Cancer Inst. 66:239-247(1981)

PubMed=7459858
Rousset M., Zweibaum A., Fogh J.
Presence of glycogen and growth-related variations in 58 cultured human tumor cell lines of various tissue origins.
Cancer Res. 41:1165-1170(1981)

PubMed=6278935
Kyriazis A.P., Kyriazis A.A., Scarpelli D.G., Fogh J., Rao M.S., Lepera R.
Human pancreatic adenocarcinoma line Capan-1 in tissue culture and the nude mouse: morphologic, biologic, and biochemical characteristics.
Am. J. Pathol. 106:250-260(1982)

PubMed=6582512; DOI=10.1073/pnas.81.2.568
Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.
Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

PubMed=8026879; DOI=10.1002/ijc.2910580207
Berrozpe G., Schaeffer J., Peinado M.A., Real F.X., Perucho M.
Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer.
Int. J. Cancer 58:185-191(1994)

PubMed=8286197; DOI=10.1038/bjc.1994.24
Lohr M., Trautmann B., Gottler M., Peters S., Zauner I., Maillet B., Kloppel G.
Human ductal adenocarcinomas of the pancreas express extracellular matrix proteins.
Br. J. Cancer 69:144-151(1994)

PubMed=10027410; DOI=10.1016/S0002-9440(10)65298-4
Ghadimi B.M., Schrock E., Walker R.L., Wangsa D., Jauho A., Meltzer P.S., Ried T.
Specific chromosomal aberrations and amplification of the AIB1 nuclear receptor coactivator gene in pancreatic carcinomas.
Am. J. Pathol. 154:525-536(1999)

PubMed=11169957; DOI=10.1002/1097-0215(200002)9999:9999<::AID-IJC1014>3.0.CO;2-U
Wallrapp C., Hahnel S., Boeck W., Soder A., Mincheva A., Lichter P., Leder G., Gansauge F., Sorio C., Scarpa A., Gress T.M.
Loss of the Y chromosome is a frequent chromosomal imbalance in pancreatic cancer and allows differentiation to chronic pancreatitis.
Int. J. Cancer 91:340-344(2001)

PubMed=12692724; DOI=10.1007/s00428-003-0784-4
Sipos B., Moser S., Kalthoff H., Torok V., Lohr M., Kloppel G.
A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform.
Virchows Arch. 442:444-452(2003)

PubMed=14695172
Iacobuzio-Donahue C.A., Ashfaq R., Maitra A., Adsay N.V., Shen-Ong G.L., Berg K., Hollingsworth M.A., Cameron J.L., Yeo C.J., Kern S.E., Goggins M., Hruban R.H.
Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies.
Cancer Res. 63:8614-8622(2003)

PubMed=18380791; DOI=10.1111/j.1349-7006.2008.00779.x
Suzuki A., Shibata T., Shimada Y., Murakami Y., Horii A., Shiratori K., Hirohashi S., Inazawa J., Imoto I.
Identification of SMURF1 as a possible target for 7q21.3-22.1 amplification detected in a pancreatic cancer cell line by in-house array-based comparative genomic hybridization.
Cancer Sci. 99:986-994(2008)

DOI=10.4172/jpb.1000057
Masayo Y., Kiyonaga F., Koji K., Setsuo H., Tadashi K.
The proteomic profile of pancreatic cancer cell lines corresponding to carcinogenesis and metastasis.
J. Proteomics Bioinform. 2:1-18(2009)

PubMed=20418756; DOI=10.1097/MPA.0b013e3181c15963
Deer E.L., Gonzalez-Hernandez J., Coursen J.D., Shea J.E., Ngatia J., Scaife C.L., Firpo M.A., Mulvihill S.J.
Phenotype and genotype of pancreatic cancer cell lines.
Pancreas 39:425-435(2010)

PubMed=22109279; DOI=10.1007/s13577-011-0037-9
Ding Q., Yoshimitsu M., Kuwahata T., Maeda K., Hayashi T., Obara T., Miyazaki Y., Matsubara S., Natsugoe S., Takao S.
Establishment of a highly migratory subclone reveals that CD133 contributes to migration and invasion through epithelial-mesenchymal transition in pancreatic cancer.
Hum. Cell 25:1-8(2012)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=25167228; DOI=10.1038/bjc.2014.475
Hamidi H., Lu M., Chau K., Anderson L., Fejzo M., Ginther C., Linnartz R., Zubel A., Slamon D.J., Finn R.S.
KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition.
Br. J. Cancer 111:1788-1801(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=27259358; DOI=10.1074/mcp.M116.058313
Humphrey E.S., Su S.-P., Nagrial A.M., Hochgrafe F., Pajic M., Lehrbach G.M., Parton R.G., Yap A.S., Horvath L.G., Chang D.K., Biankin A.V., Wu J., Daly R.J.
Resolution of novel pancreatic ductal adenocarcinoma subtypes by global phosphotyrosine profiling.
Mol. Cell. Proteomics 15:2671-2685(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

Cross-references
Cell line collections AddexBio; C0018001/31
ATCC; HTB-79
BCRJ; 0265
CLS; 300143/p663_Capan-1
DSMZ; ACC-244
IZSLER; BS TCL 9
KCLB; 30079
Cell line databases/resources CLDB; cl639
CLDB; cl640
CCLE; CAPAN1_PANCREAS
CGH-DB; 162-1
CGH-DB; 9269-4
Cosmic-CLP; 753624
GDSC; 753624
IGRhCellID; Capan1
LINCS_LDP; LCL-1732
Lonza; 1011
SKY/M-FISH/CGH; 1999
TOKU-E; 773
Ontologies BTO; BTO:0002744
CLO; CLO_0002197
EFO; EFO_0002153
MCCL; MCC:0000126
Biological sample resources BioSample; SAMN01821543
BioSample; SAMN01821620
BioSample; SAMN03471999
Chemistry resources ChEMBL-Cells; CHEMBL3307640
ChEMBL-Targets; CHEMBL614536
Gene expression databases GEO; GSM206452
GEO; GSM621902
GEO; GSM784706
GEO; GSM886920
GEO; GSM887986
GEO; GSM1024398
GEO; GSM1374438
GEO; GSM1374439
GEO; GSM1669663
Polymorphism and mutation databases Cosmic; 724646
Cosmic; 736270
Cosmic; 753624
Cosmic; 755302
Cosmic; 808173
Cosmic; 872997
Cosmic; 913302
Cosmic; 922252
Cosmic; 923166
Cosmic; 932516
Cosmic; 933521
Cosmic; 947395
Cosmic; 948374
Cosmic; 948726
Cosmic; 949231
Cosmic; 1006365
Cosmic; 1090399
Cosmic; 1108338
Cosmic; 1122342
Cosmic; 1198205
Cosmic; 1299296
Cosmic; 1320462
Cosmic; 1534317
Cosmic; 1571774
Cosmic; 1761694
Cosmic; 1995362
Cosmic; 2434105
Proteomic databases PRIDE; PXD003198